Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New technology makes clinical research more precise

12.12.2006
The Flanders Interuniversity Institute for Biotechnology (VIB) and AlgoNomics have joined forces to develop a technology that verifies whether certain proteins induce an immune response in humans.

The collaboration between VIB and AlgoNomics has yielded a biological test that supplements the current computer simulations. The additional data enable a more precise determination of the immune response. This knowledge is important for the development of new medicines, because it indicates that a new therapeutic substance is ready to be tested on humans.

T-cells, essential agents of our immune system

The immune system is our defense against foreign intruders, such as viruses and bacteria. It reacts against everything that it recognizes as ‘foreign to the body’ - but, therefore, it might also react against certain substances that researchers want to develop into therapeutic drugs. An important trigger of the immune system’s response is the activation of T-cells, a particular type of white blood cell. The T-cells produce cytokines, substances that signal the other cells of the immune system to take action.

Developing therapeutic proteins

In the development of new therapeutic proteins, it is extremely important to know whether or not the proteins induce an immune response. When you suspect that a certain substance has a therapeutic effect, it must not be destroyed by your immune system, or induce other immune responses, because you want the substance to be able to do its beneficial work.

On the other hand, when developing a vaccine, you do want it to induce an immune response - that is, a reaction that does not make you sick but that protects you against future contact with the disease that the vaccine combats.

Epibase, an ‘in silico’ test

For quite some time now, AlgoNomics has been offering Epibase to companies that are developing therapeutic proteins and that want to know whether their product induces an immune response. On the basis of a sophisticated computer program, Epibase can predict whether or not a particular protein will trigger the activation of T-cells. The technology can do this for all proteins, whether they originate from humans or from another biological source, such as a virus or a cancer cell. The marvelous thing about Epibase is that it can also do this for proteins for which little or no experimental data are available. Other technologies require at least a minimum of data to predict whether a substance induces an immune response or not. Epibase has already been used for the development of a variety of therapeutic proteins and is currently the biotech industry standard. In contrast to other ‘in silico’ platforms, Epibase provides greater precision and can predict immune response in Asian and South American populations as well.

A more complete test

Upon the request of AlgoNomics, VIB scientists connected with Ghent University, under the direction of Johan Grooten, have designed a biological test that supplements the Epibase assessments with certain experimental data. The test exposes blood cells - which include T-cells - to the proteins under study. If the proteins being investigated induce an immune response, the T-cells will become active and produce cytokines. In this new test, the activity of the T-cells is measured by determining the quantity of cytokines that are produced.

The new test allows scientists to examine a biological system to see whether a substance induces an immune response. For the step to a clinical phase (and thus tests on humans), the experimental and ‘in silico’ data are both needed to assess the risk of inducing an immune response. Thanks to the collaboration between VIB and AlgoNomics, it is now possible to generate all the data by means of a single test - an artful combination of ‘in silico’ and ‘in vitro’ work.

Sooike Stoops | alfa
Further information:
http://www.vib.be

Further reports about: AlgoNomics Epibase T-Cells immune immune response induce silico’ therapeutic

More articles from Life Sciences:

nachricht Repairing damaged hearts with self-healing heart cells
22.08.2017 | National University Health System

nachricht Biochemical 'fingerprints' reveal diabetes progression
22.08.2017 | Umea University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

Cholesterol-lowering drugs may fight infectious disease

22.08.2017 | Health and Medicine

Meter-sized single-crystal graphene growth becomes possible

22.08.2017 | Materials Sciences

Repairing damaged hearts with self-healing heart cells

22.08.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>